Corporate Strategy Consulting
in HealthTech & Digital Health

The short answer

Most people who go looking for corporate strategy in digital health have a business-unit question, and the two have opposite answers. Digital health companies carry a specific bind here — outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle. Until that is priced, at-risk revenue share will keep moving for reasons nobody can attribute, and the debate about return on capital by unit will stay a matter of opinion.

The distinction is not academic. Corporate strategy asks where to play: which contracts and risk-sharing arrangements to hold, what partnerships to form, how capital moves between member cohorts, and what the corporate centre does that justifies its cost. Business-unit strategy asks how to win: raising engagement rate, improving attributed outcomes, managing at-risk share, and reducing logo churn on a specific book of business. Both are legitimate; they use different evidence and produce different decisions.

The reason they get confused is that the symptom is often identical. Flat consolidated ARR looks the same whether the cause is one underperforming contract or a set of arrangements that have drifted into unrelated risk profiles. The test is what happens when you disaggregate: if performance is uniform across cohorts, you have a competitive problem in engagement or outcomes delivery and the portfolio view will not find it. If the average is being made by one contract carrying two, you have a portfolio problem and no amount of tweaking PMPM or attributed outcomes inside the weak contracts will fix it.

The second thing corporate strategy is for, and the one most often skipped, is the parenting question — what the centre adds. A corporate centre earns its cost either by allocating capital across at-risk arrangements better than the market would, by supplying outcomes measurement or risk management the contracts could not buy alone, or by imposing discipline on engagement rate and logo churn the units would not impose on themselves. If it does none of those, it is a tax on the contracts, and the honest strategic answer may be to shrink it rather than to redirect it.

Corporate Strategy & Transformation runs the portfolio arithmetic — return on capital by contract, contribution against capital consumed, the overhead each arrangement actually carries — and produces the allocation view. Where the answer turns out to be a single-contract competitive question, it will say so and point at the narrower analysis rather than dressing an engagement-rate or outcomes problem in portfolio language.

How to tell this is actually your problem

These three together are the signature. One on its own usually points somewhere else.

✓ The group ARR is flat and the contracts inside it are not moving together on engagement rate or logo churn
✓ Nobody can state what the corporate centre does that a contract could not buy on its own for measuring or carrying outcomes risk
✓ Capital is allocated roughly in proportion to last year’s enrolled members rather than to return on at-risk share

The move that usually makes it worse. Running a portfolio review on a company that is really one set of outcomes contracts, which produces a recommendation to divest the part that was about to become the answer.

Who this is for — and who it is not

It is for you if you run or finance a digital health company and the group result is flat and the units inside it are not moving together. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.

It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.

What this looks like when the analysis is actually run

Below is an excerpt from a real run of this analysis on a digital health company. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.

The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.

This is one move out of a full analysis. Read a complete report — every page, no email required.

What the engine does with this question

This question routes to Corporate Strategy & Transformation, one of 29 engagements the platform runs. For digital health companies it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.

You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.

Questions people ask about this

What is the difference between corporate strategy and business strategy?

Corporate strategy decides which businesses to be in and how capital moves between them. Business strategy decides how to win inside one of them. A single-market company has no corporate strategy question worth paying for — it has a competitive one. A group with three units and one balance sheet has both, and answering them in the wrong order is the common failure.

What does corporate strategy consulting cost?

A portfolio review from a large firm is commonly £150k–£500k for eight to twelve weeks; boutiques and independents do narrower versions for £40k–£120k. The variance is driven almost entirely by how much primary data collection is in scope. If your own finance system can already produce contribution and capital by unit, most of that cost is buying analysis of numbers you already hold.

Is a BCG matrix still a useful way to look at a portfolio?

As a summary, yes; as a decision rule, no. Growth and share are two of the variables that matter and they are the easiest two to obtain, which is why the matrix persists. It becomes misleading when a unit with modest share is the one generating the cash that funds everything else, and the grid says to divest it. Use it to organise the conversation, then decide on return against capital consumed.

Is this different in healthtech & digital health than in other industries?

Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.

What data do I need before this analysis is worth running for a digital health company?

Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.

When is Percision the wrong tool?

Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Does Percision replace a lawyer, tax advisor, auditor, or AI implementation team?

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.